Synthesis and Distribution of Drugs of Abuse and Related Compounds

SOL #: 75N95022D00016Pre-Solicitation

Overview

Buyer

Health And Human Services
National Institutes Of Health
NATIONAL INSTITUTES OF HEALTH NIDA
Bethesda, MD, 20892, United States

Place of Performance

Place of performance not available

NAICS

Research and Development in the Physical (541715)

PSC

Health R&D Services; Health Care Services; Basic Research (AN11)

Set Aside

No set aside specified

Timeline

1
Posted
Jan 30, 2026
2
Last Updated
May 13, 2026
3
Response Deadline
May 28, 2026, 5:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has issued a Notice of Intent to Award a Sole Source Modification to Research Triangle Institute for the "Synthesis and Distribution of Drugs of Abuse and Related Compounds" contract (No. 75N95022D00016). This modification will increase the existing Single Award Indefinite Delivery, Indefinite Quantity (IDIQ) contract's maximum value by $3,718,289, raising it from $14,004,330 to $17,722,619. The purpose is to ensure the uninterrupted continuation of critical support services for scientific research on substance use and drug dependence, and to address an increased need for drug products for clinical trials, while a new contract is planned and competed.

Scope of Work

The existing contract, which this modification supports, provides essential services including:

  • Production and distribution of labeled and unlabeled drugs of abuse and research compounds.
  • Analysis, testing, and maintenance of purity for NIDA's drug supply inventory.
  • Replenishment of depleted drug/chemical substances through synthesis or acquisition.
  • Identification, acquisition, storage, and updating of the drug supply inventory with new compounds.
  • Maintenance and updating of the NIDA drug supply database (DISCS).

Contract & Timeline

  • Type: Sole Source Modification to an existing Single Award IDIQ (75N95022D00016)
  • Current Contractor: Research Triangle Institute
  • Increased Value: $3,718,289 (New maximum: $17,722,619)
  • Ordering Period: June 9, 2022 to June 8, 2027 (unchanged)
  • NAICS Code: 541715 (Research and Development in the Physical, Engineering, and Life Sciences)
  • Response Due: May 28, 2026, 1:00 p.m. EDT
  • Published: May 13, 2026

Regulatory & Statutory Basis

This action is conducted under the authority of 10 U.S.C. 3204(a)(1) or 41 U.S.C. 3304(a)(1) and FAR 6.103-1, citing "Only one responsible source and no other supplies or services will satisfy agency requirements." The modification is necessary to prevent delays or disruption of support services for ongoing and upcoming pre-clinical and clinical trials.

Action Items

This is not a request for competitive proposals. However, interested parties may submit capability statements or objections to the proposed sole source modification. The Government will consider responses but retains sole discretion to proceed non-competitively. All responses must be received by the deadline and sent electronically to Shaun Rostad at shaun.rostad@nih.gov. An active SAM.gov registration, UEI, TIN, and certification of business size are required for any potential offeror.

People

Points of Contact

Shaun RostadPRIMARY
Joshua T LazarusSECONDARY

Files

Files

No files attached to this opportunity

Versions

Version 2Viewing
Pre-Solicitation
Posted: May 13, 2026
Version 1
Special Notice
Posted: Jan 30, 2026
View
Synthesis and Distribution of Drugs of Abuse and Related Compounds | GovScope